In advanced breast cancer patients receiving bevacizumab and vinorelbine who had lower baseline plasma VEGFA before treatment had longer time to progress (9.3 months vs. 3.7 months) than those with higher plasma VEGFA [48]. Here, VEGFA is linked to breast carcinoma.